Belite Bio (BLTE) to Release Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Price Performance

Shares of NASDAQ:BLTE opened at $62.66 on Monday. The company has a market capitalization of $1.99 billion, a PE ratio of -56.45 and a beta of -1.52. Belite Bio has a 1 year low of $40.00 and a 1 year high of $86.53. The business has a fifty day moving average price of $61.52 and a two-hundred day moving average price of $63.14.

Analysts Set New Price Targets

Several brokerages have commented on BLTE. Benchmark reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Belite Bio in a research report on Wednesday, March 26th. Cantor Fitzgerald reissued an "overweight" rating on shares of Belite Bio in a research report on Tuesday, March 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Belite Bio in a research report on Tuesday, March 18th.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.